A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells

[1]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[2]  D. Schaid,et al.  Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Brachman,et al.  Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes , 1991, Journal of surgical oncology.

[4]  I. Mett,et al.  A protein related to a proteasomal subunit binds to the intracellular domain of the p55 TNF receptor upstream to its ‘death domain’ , 1995, FEBS letters.

[5]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[6]  AC Tose.  Cell , 1993, Cell.

[7]  J. Roth,et al.  A Recombinant Adenovirus Expressing Wild-Type Bax Induces Apoptosis in Prostate Cancer Cells Independently of Their Bcl-2 Status and Androgen Sensitivity , 2002, Cancer biology & therapy.

[8]  J. Roth,et al.  Safety Evaluation of Ad5CMY-p53 In Vitro and In Vivo , 1995 .

[9]  J. Roth,et al.  Clinical update of Ad-p53 gene therapy for lung cancer. , 2002, Surgical oncology clinics of North America.

[10]  I. Nagata,et al.  Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. , 1999, European journal of cancer.

[11]  N. Mailand,et al.  Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.

[12]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[13]  John Calvin Reed,et al.  Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. , 2000, Neoplasia.

[14]  S. Lippman,et al.  Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[16]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[17]  G. D. Pearson,et al.  Deletion of the Saccharomyces cerevisiae TRR1 Gene Encoding Thioredoxin Reductase Inhibits p53-dependent Reporter Gene Expression* , 1998, The Journal of Biological Chemistry.

[18]  T. Shenk,et al.  Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Bergh,et al.  Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors , 2000, Cancer Gene Therapy.

[20]  Yusuke Nakamura,et al.  p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53 , 2000, Cell.

[21]  C. Prives,et al.  A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis , 1996, Molecular and cellular biology.

[22]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[23]  J. Moul.  Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy , 1999, European Urology.

[24]  Susan M. Chang,et al.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[26]  J. Bartek,et al.  Mammalian G1- and S-phase checkpoints in response to DNA damage. , 2001, Current opinion in cell biology.

[27]  D. Voehringer,et al.  Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols , 1997, Oncogene.

[28]  E. Gelmann,et al.  p53 oncogene mutations in three human prostate cancer cell lines , 1993, The Prostate.

[29]  T. McDonnell,et al.  Bcl-2 accelerates multistep prostate carcinogenesis in vivo , 2000, Oncogene.

[30]  C. Prives,et al.  Covalent and noncovalent modifiers of the p53 protein , 1999, Cellular and Molecular Life Sciences CMLS.

[31]  L. Pagliaro.  Gene therapy for bladder cancer , 2000, World Journal of Urology.

[32]  D. Green,et al.  p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release* , 2000, The Journal of Biological Chemistry.

[33]  J. Ott,et al.  The p53MH algorithm and its application in detecting p53-responsive genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[35]  J. Blenis,et al.  Essential Role for Caspase-8 in Transcription-independent Apoptosis Triggered by p53* , 2000, The Journal of Biological Chemistry.

[36]  E. Chang,et al.  Does p53 status influence tumor response to anticancer therapies? , 2000, Anti-cancer drugs.

[37]  C. Auffray,et al.  The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. , 1996, Genomics.

[38]  Keiji Tanaka,et al.  The 26S proteasome: subunits and functions , 1997, Molecular Biology Reports.

[39]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[40]  M. Dickman,et al.  Bcl-2 family members inhibit oxidative stress-induced programmed cell death in Saccharomyces cerevisiae. , 2003, Free radical biology & medicine.

[41]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[42]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[43]  Tong-Yuan Yang,et al.  Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer , 2003, Cancer Gene Therapy.

[44]  E. Shaulian,et al.  Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.

[45]  Peng Huang,et al.  Superoxide dismutase as a target for the selective killing of cancer cells , 2000, Nature.

[46]  D. Voehringer,et al.  Redox aspects of Bcl-2 function. , 2000, Antioxidants & redox signaling.

[47]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[48]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[49]  T. McDonnell,et al.  Bcl-2 inhibits p53 nuclear import following DNA damage , 1997, Oncogene.

[50]  S. Hoffmann,et al.  Role and Function of the 26S Proteasome in Proliferation and Apoptosis , 2002, Laboratory Investigation.

[51]  P. Tegtmeyer,et al.  Role of cysteine residues in regulation of p53 function , 1995, Molecular and cellular biology.

[52]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[53]  Moshe Oren,et al.  The p53 and Mdm2 families in cancer. , 2002, Current opinion in genetics & development.

[54]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[55]  T. McDonnell,et al.  Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53 , 1998, Oncogene.

[56]  D. Voehringer,et al.  Bcl-2 expression causes redistribution of glutathione to the nucleus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. Andrews,et al.  Inhibition of p53 Transcriptional Activity by Bcl-2 Requires Its Membrane-anchoring Domain* , 1999, The Journal of Biological Chemistry.

[58]  A. Fornace,et al.  Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress , 1999, Oncogene.

[59]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[60]  W. R. Bishop,et al.  Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway , 2002, Oncogene.

[61]  D. Green,et al.  Mechanisms of p53-dependent apoptosis. , 2001, Biochemical Society transactions.

[62]  C. Dive,et al.  Apoptosis and cancer chemotherapy. , 2001, Trends in cell biology.

[63]  T. McDonnell,et al.  Bcl-2 suppresses apoptosis resulting from disruption of the NF-κB survival pathway , 1997 .

[64]  M. Shelanski,et al.  Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Karin,et al.  p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.

[66]  Jiandong Chen,et al.  Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53* , 2002, The Journal of Biological Chemistry.

[67]  T. McDonnell,et al.  TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2 , 2001, Oncogene.

[68]  B. Trump,et al.  BCL-2 is involved in preventing oxidant-induced cell death and in decreasing oxygen radical production , 2001, Redox report : communications in free radical research.

[69]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[70]  A. Fornace,et al.  Death and decoy receptors and p53-mediated apoptosis , 2000, Leukemia.

[71]  D. Voehringer.  BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. , 1999, Free radical biology & medicine.

[72]  M. Brimmell,et al.  Bcl-2-related proteins and cancer. , 1999, Biochemical Society transactions.

[73]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[74]  Yaolin Wang,et al.  Analyses of p53 Target Genes in the Human Genome by Bioinformatic and Microarray Approaches* 210 , 2001, The Journal of Biological Chemistry.

[75]  T. McDonnell,et al.  Human keratin-1.bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation , 1998, Oncogene.

[76]  N. Hay,et al.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.

[77]  J. Roth,et al.  Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. , 2001, International journal of cancer.

[78]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[79]  L. Latonen,et al.  Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. , 2002, Nucleic acids research.

[80]  K. Vousden,et al.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.

[81]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[82]  T. McDonnell,et al.  Molecular markers of outcome after radiotherapy in patients with prostate carcinoma , 2003, Cancer.